Tuesday, July 21, 2026

The Cancer News

AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER

Cancer Education

Resources for Cancer Patients

Clinical Breakthroughs & Research

Oncology Without Borders

Article Submission

The Cancer News

Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer

Research · Cancer Education

Precision Over Protocol: What's New in HR-Positive, HER2-Negative Breast Cancer

Hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer is the most common subtype of breast cancer and its treatment landscape has never been more complex or more promising.

By Sasha Stanton, MD, PhD

Research · Cancer Education

Prostate Cancer at ASCO 2026: Perioperative Intensification Changes the High-Risk Localized Landscape, PARP Inhibitors Move Earlier, and De-escalation Data Arrives

Prostate Cancer at ASCO 2026: Perioperative Intensification Changes the High-Risk Localized Landscape, PARP Inhibitors Move Earlier, and De-escalation Data Arrives

by Alexandra Sokolova, MD

Research · Cancer Education

Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist

Clinical Review of Cellular Therapies for Multiple Myeloma Part II: Toxicities of CAR-T for the Community and Rural Oncologist

by Adeel M Khan MD MPH MS; Aimaz Afrough, MD; Samer Al Hadidi, MD, MS; Sean Taasan, MD; Larry D Anderson Jr, MD, PhD

Top Stories

Cancer Education · Research

CAR-T Cell Therapy for Relapsed Aggressive Lymphoma: Who to Refer, When, and What's Coming Next

July 17, 2026

Bladder Cancer at ASCO 2026: A New Standard in Non-Muscle Invasive Disease, Intravesical Approaches in Muscle-Invasive Disease, and Three and a Half Years of Enfortumab Vedotin Data

July 14, 2026

Cancer Education · Research

New Drugs, New Standards: What's Changing in Gastroesophageal Cancer Treatment

July 13, 2026

Research · Cancer Education

Upper GI Cancers at ASCO 2026: A New HER2-Positive Standard, a Negative Dual-IO Trial, and Two Signals From Asia

July 11, 2026

Research · Cancer Education

HCC and Pancreatic Cancer at ASCO 2026: TACE Combinations Move Forward in Liver Cancer, and Daraxonrasib Rewrites the Standard of Care in Pancreatic Cancer

July 10, 2026

Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist

Research · Cancer Education

Clinical Review of Cellular Therapies for Multiple Myeloma Part I: A Primer on CAR-T for the Community and Rural Oncologist

Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology

Research · Cancer Education

Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology

Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure

Research · Perspectives

Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure

ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer

Research · Perspectives

ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer

Cancer Education

Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026

2026-07-20

Colorectal Cancer at ASCO 2026: When to Stop Immunotherapy, How to Use BRAF-Targeted Therapy, and Why Exercise Belongs in the Treatment Plan

2026-07-09

Small Cell Lung Cancer in 2026: A Field That Has Finally Started Moving

2026-06-23

Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything

2026-06-16

Research

Daraxonrasib: The New Pancreatic Cancer Drug Patients Can Access Now through Clinical Trial Showing Promising Results

2026-07-01

Multiple Myeloma and Plasma Cell Disorders in 2026: Bispecifics Move Earlier, MRD Guides Duration, and Amyloidosis Finally Has a Target

2026-06-29

Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter

2026-06-25

Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer

2026-06-24

Health Equity

CAR-T's Real Toxicity Is Delay

2026-06-18

Why a Child's Zip Code May Be Their Most Important Cancer Prognostic Factor

2026-06-16

"I Think of Myself as a Plumber": The Engineer Trying to Fix Global Diagnostic Inequity

2026-06-10

Where You Live Matters: How Neighborhood Conditions Shape Cancer Outcomes and Survival Disparities

2026-04-01

Perspectives

Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming

2026-07-16

ASCO 2026: Expert Commentary on the SUCCESSOR-2 Trial in Relapsed/Refractory Multiple Myeloma

2026-06-13

ASCO 2026: Sunvozertinib & Selpercatinib in Lung Cancer

2026-06-13

Sarcoma Treatment in 2026: From Gerald Ford’s Drugs to Trabectedin and Pembrolizumab

2026-06-11

Resources for Cancer Patients

Soy and Breast Cancer: Is It Safe to Eat Tofu?

2026-06-12

What Is Metastatic Cancer? Understanding When and How Cancer Spreads

2026-02-17

Header image for article “The Hidden Role of Physical Therapy in Breast Cancer Survivorship,” featuring Dr. Rebecca Miller and a pink breast cancer ribbon.

The Hidden Role of Physical Therapy in Breast Cancer Survivorship

2025-10-16

Breast Cancer 101 title graphic on pink background with Binaytara icon.

Breast Cancer 101

2025-10-02

Health Policy

Rural Cancer Care and the Dollar Sign on Your Diagnosis

2026-06-25

What Does Oncology Have to Do With Advocacy, Anyway?

2026-06-05

Asking Because We Care: Why SOGI Data Is Essential to Equitable Cancer Care

2026-06-04

The Effect of Changing Politics on Global Health

2025-12-19

Get the Quick Bites delivered to your inbox daily